Etretinate
Generic medicine reference
Not yet clinically reviewed
This entry was migrated from the earlier Pharmapedia app bundle and has not been reviewed by a named clinician on this site. It is provided for educational reference only — verify dosage and safety information against current, authoritative sources and a qualified healthcare professional before any clinical use.
Overview
Etretinate is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. Etretinate is anticipated that in the near future it will most likely be replaced by its active metabolite etretin because of latter shorter elimination half life.
Indications
Etretinate is primarily indicated in conditions like Autosomal dominant ichthyosis, Bullous dermatoses, Dariers disease, Epidermal neoplastic disorders, Keratinization disorders, Lichen planus, Nevus unius lateris, Psoriasis, Sex-linked ichthyosis.
Contraindications
Etretinate is contraindicated in conditions like Diabetes mellitus,Pregnancy.
Side Effects
The severe or irreversible adverse effects of Etretinate, which give rise to further complications include Congenital malformation, Abortions, Hyperlipidemic effects, Osseous abnormalities, Intracranial hypertension. Etretinate produces potentially life-threatening effects which include Hepatotoxicity, Vit A over dosage, Elevation of liver enzymes, which are responsible for the discontinuation of Etretinate therapy.The signs and symptoms that are produced after the acute over dosage of Etretinate include Drowsiness, Irritability, Vit A poisoning, Severe headache, Nausea & vomiting. The symptomatic adverse reactions produced by Etretinate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Itching, Cheilitis, Conjunctivitis, Nasal bleeding, Eczematous rash.
Warnings
It should be used with caution in patients with acute, severe and progressive disturbances of consciousness. Administered with hemostatic intracranial pressure relieving drugs or use measures to keep body temperature low.
High Risk Groups
Drug should not be given to Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Adult Dosage
0.25 to 0.5 mg/kg (0.38 (0.375)) 24 hourly PO — -
Child Dosage
No child dosage information is recorded for this medicine yet.
Neonatal Dosage
No neonatal dosage information is recorded for this medicine yet.
Drug Interactions
Etretinate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementMethotrexateEtretinate potentiate the risk of hepatitis when it is given with methotrexate.MajorCombination is considered contraindicated.Phenytoin (Na)Retinol (Vitamin A)Tetracycline (HCl) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Storage
Cap Store at room temperature. Protect from Sunlight.
Available Brands in Pakistan
No brands are recorded for this generic.